Dr Tommy Fluen stated, “We look forward to working with PharmAust and trial Principal Investigator Dr Kim Agnew to test the hypothesis that monepantel will provide a well-tolerated oral therapy for canines with lymphoma, which is superior to steroids alone and without the costs and risks of chemotherapy.”
Principal Investigator Dr Kim Agnew stated, “It is always very beneficial for any product development building towards a Phase 3 study to expand knowledge in new market settings so having the NZ team combine with our team is very good for the PharmAust program.”
PharmAust’s Chief Scientific Officer Dr Richard Mollard stated, “PharmAust is delighted to work with Dr Coleman, Dr Fluen and Dr McNab to establish a clinical trial site in New Zealand. Establishing trial procedures, structures and systems with these groups and receiving their feedback will provide great value to PharmAust in preparing for Phase 3 and potentially later with product roll-out.”
